• HAVN Life (HAVN) has secured a product listing with Loblaw (L), Canada’s largest grocery retailer
  • Loblaw will carry 6 of 11 HAVN Life natural health products nationally under store banners Atlantic Superstores, YIG (Your Independent Grocer), Dominion, Loblaws, Zehrs and Real Canadian Superstore
  • CEO Tim Moore spoke with Daniella Atkinson about the news
  • HAVN Life Sciences is a biotechnology company extracting psychedelic compounds to develop APIs, natural health products, and therapies to support brain health and immune function
  • HAVN Life Sciences (HAVN) is unchanged trading at $0.095 per share

HAVN Life (HAVN) has secured a product listing with Loblaw (L), Canada’s largest grocery retailer.

Loblaw will carry 6 of 11 HAVN Life natural health products nationally under store banners Atlantic Superstores, YIG (Your Independent Grocer), Dominion, Loblaws, Zehrs and Real Canadian Superstore.

Products are expected to hit shelves in November 2022.

The listing marks HAVN’s first partnership with a national retailer.

CEO Tim Moore spoke with Daniella Atkinson about the news and what it means for the company moving forward.

Fortinos, which approved HAVN for distribution in July 2022, has also approved the company’s Brain Evolve series of performance-enhancing supplements, which are also expected on shelves this November.

HAVN Life Sciences is a biotechnology company extracting psychedelic compounds to develop APIs, natural health products, and therapies to support brain health and immune function. Its formulations are non-GMO, vegan, bioavailable and naturally derived from plants and functional mushrooms.

HAVN Life Sciences (HAVN) is unchanged trading at $0.095 per share as of 1:39 pm ET.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.